We all want to live long healthy lives – as evidenced by the multi-trillion dollar wellness industry.
In our pursuit for healthy living, there are an overwhelming number of diets, fitness apps and exercise programs to choose from. The problem is that finding what works for you can be hit and miss. This is because we are all genetically different.
Fitgenes helps to take the guesswork out of wellness planning. Take weight loss as an example. CarbChoice by Fitgenes is a simple home DNA test. For $149 it identifies an individual’s response to a key dietary issue with a genetic trigger and gives a plan for success. There is much more. FoodChoice by Fitgenes reports on the genetic risk of food intolerances and sensitivities and the risk of food allergies, while the company’s flagship Health and Wellbeing Report is supplied exclusively to practitioners to assist in the assessment and management of chronic diseases, immunity issues and weight management. With the support of the Fitgenes Accredited Health Practitioners network, this knowledge becomes applied precision wellness – a roadmap to live a long and healthy life.
FITGENES - Personalised DNA-based, wellness plans - tailored, reliable, affordable, and accessible
The global wellness genomics market is high-growth with 13.2% CAGR; and predicted to hit US$9 billion by 2026. Nutrigenomics, a subset of that market, is set to double in the next few years to approximately $1 billion.
Fitgenes business model not only delivers tailored, reliable, affordable and accessible wellness plans, its plans are integrated with a growing allied health network of practitioners – in other words, has a unique distribution channel that makes its test results even more meaningful.
With increased adoption of DNA-based testing by health professionals, Fitgenes is building its pipeline amongst the 830,000+ medical doctors in the USA, and over 43,000 GPs in Australia, as well as the additional millions of allied health professionals globally.
This pipeline is being developed to increase Fitgenes’ already healthy 11% year on year growth in business income.
As a pioneer of genetics-based health management, Fitgenes has used technology advances to significantly improve report quality, take advantage of decrease testing costs and improve scalability. Here are some recent progress highlights:
Fitgenes achieved 11% income growth in 2020 over 2019, during COVID and prior to adding new distribution partners.
While the connection between genetics and nutrition is well known, until recently, the ability to commercialise DNA-based health solutions has been limited due to high cost of testing and regulatory restrictions. As a result, the market to date has been dominated by commoditised direct-to-consumer reports that can lack scientific rigour and often void of essential context, such as a person’s goals, stage of life or existing health status.
However, this ‘isolated’ testing model is under threat, with medical research consensus and regulatory requirements strengthening in favour of practitioner delivery of DNA-based health and wellness reports.
Fitgenes’ business model has a primary focus that practitioner channel, with a network of accredited health practitioners using and trained in our methodology.
People are living longer but are not living better – the last 20 years of a modern lifespan are very often marred by debilitating chronic disease. Implementing nutrition, dietary, lifestyle and even exercise advice based on your unique DNA has been demonstrated to assist in the prevention and management of long-term health, of many acute diseases and to assist weight management and has increasing mainstream acceptance (AMA Australia, 2020).
Fitgenes is an innovative DNA-based healthcare business focused on long-term wellness, obesity and cardiometabolic health. We are an early mover in the growing global nutrigenomics (DNA testing for dietary health) industry and the increasing shift to the biomedical-driven prevention of chronic disease, including but not limited to, obesity, diabetes, cardiovascular disease, poor immune function, and to improve sports performance, injury prevention and recovery.
An investment in Fitgenes provides an opportunity to participate in the most-established DNA wellness provider in the practitioner channel, as that sector expands while the direct to consumer market is threatened by greater regulatory controls, commoditisation, and lack of medical industry acceptance.
Polymetals Resources Ltd (ASX: POL) owns two exploration licences within the Siguiri Basin in Guinea, West Africa. The Siguiri Basin occupies the north-eastern corner of Guinea and hosts several large active gold mining operations and is notable for its widespread gold anomalism. The region is considered prospective and relatively immature from an exploration perspective and produces over 500,000 oz of gold/year. The nearby AngloGold Ashanti Siguiri Gold Mine, has produced more than six (6) million ounces over its 20-year life.
The licence area is host to many historic and current small scale gold mining operations. The results of inititial soil sampling confirmed that 18 km2 or 16% of the area surveyed reported gold values in excess of 40ppb Au.
Update: Commitments in excess of the $5 million min offer size received
Lode Resources Ltd (ASX: LDR) is a copper, gold and silver exploration company with 6 projects and 7 granted exploration licences with tenements covering 950km2 in the New England Fold Belt of NSW. Each of the 6 projects are 100% owned and have demonstrated a high grade mineralisation and/or potential for large mineral occurrences. The strategy is to target large-scale gold, silver and copper mineral systems using modern geophysical exploration methods and advance discoveries to the development stage.
All exploration licences are fully granted and owned by Lode Resources. Considerable historical work has delivered significant and encouraging geological data, providing an opportunity for discoveries.
The COVID-19 pandemic has caused a wave of discounted capital raisings with ~$53 billion of discounted new shares issued in the last 12 months.
Share Purchase Plans (SPPs) allow individual shareholders to apply for up to $30,000 in shares at the same discounted price paid by institutions. In the 12 months to 31 December, in-the-money SPPs were issued at an average 10% discount to the ASX closing price on the SPP closing date. But, you must be a shareholder before the SPP is announced.
SPP HarvesterTM gives you access to SPPs by buying you 1-share in 300 of the largest, liquid, operating companies listed on ASX. It will identify and apply for in-the-money SPPs and automatically sell the new securities, efficiently recycling your capital into the next SPP. This automatically harvests the discount for SPPs, with minimum capital outlay, low establishment costs and minimal administration.
goPassport is a unique and highly relevant travel risk SaaS platform in the new Travel/Health Tech space. The business started at the outset of Covid in March 2020 and has since built out a powerful, complex but user friendly & scalable software following the successful crowd sourced equity raise of $0.8m.
Having engaged deeply with key levels of state & federal government, travel industry, health authorities and border protection agencies, goPassport is now well placed to play a vital role in the reopening of borders and the recommencement of the international travel industry.
This offer is restricted to professional, sophisticated, and experienced investors. More info here.
People spend big on wellness (it accounts for 5.3% of global economic output). But, 80% of consumers find the market is full of conflicting data, making this spend haphazard. Solving this problem is the emerging wellness genomics sector - a high-growth market (13.2% CAGR), predicted to hit US$9 billion by 2026.
Meet Fitgenes. With a range of wellness focus areas, Fitgenes’ genomic products cut through the clutter - delivering wellness plans tailored to the specific requirements of an individual. But it is the distribution network and strategy that sets this growing heath-tech business apart.
Before investing please consider the offer document and the general risk warning.
Want to learn a TikTok move? ….sure, but first ...what’s 7 x 8? Want to post to Instagram? Go for it .. but first ….. What’s the square root of 6,384 (just kidding but you get the idea).
1Question is an app that leverages existing screen habits to create micro learning moments. Lots of them. Every. Single. Day. Advanced AI understands the student’s strengths and weaknesses and customizes questions to accelerate learning.
1Question is backed by the Google accelerator program for User Acquisition. They are a company that is born global with a first mover advantage and a gigantic total addressable market.
ATO approved ESIC status delivering substantial investor tax benefits.
Before investing please consider the offer document and the general risk warning.